safety-lane.com 07105
chiropractic-lane.com
www.cbd-lane.com
www.diagnostic-lane.com
NEWARK
http://www.healthy-lane.com
GLP-1 Drugs Stop Drug and Alcohol Cravings
GLP-1 drugs appear to blunt craving by dialing down the brain’s core reward circuitry, leading to fewer overdoses, hospitalizations and new substance use disorders in large human datasets and early clinical trials.
How GLP-1 affects the brain
The gut hormone GLP-1 is also made in the brain, where its receptors cluster in regions that regulate reward, motivation and stress—the same mesolimbic circuitry disrupted in addiction. At therapeutic doses, GLP-1 drugs cross the blood–brain barrier and dampen dopamine signaling in the brain’s main reward hub, making addictive substances feel less rewarding and reducing the salience of drug cues.
Evidence from animal studies
Across multiple animal models, GLP-1 receptor agonists reduce voluntary intake of alcohol, opioids, cocaine and nicotine, and lessen relapse‑like drug seeking. In alcohol‑drinking primates, GLP-1 treatment lowers alcohol consumption without changing water intake or causing obvious sickness, suggesting a true drop in alcohol’s reward value rather than simple aversion.
Evidence from large human datasets
An analysis of more than 600,000 U.S. veterans with type 2 diabetes found that GLP-1 medications were associated with fewer new substance use disorders across alcohol, opioids, cocaine, nicotine and cannabis, and with substantial reductions in overdoses and drug‑related deaths among people already affected. Over three years, this translated to about 12 fewer serious substance‑related events and 6–7 fewer new diagnoses per 1,000 GLP-1 users.
Supporting population studies
A Swedish nationwide cohort of roughly 227,000 people with alcohol use disorder reported a 36% lower risk of alcohol‑related hospitalization among those on GLP-1 drugs, more than twice the reduction seen with naltrexone in the same analysis. Other observational studies link GLP-1 treatment to lower rates of new and recurrent alcohol use disorder, fewer health‑care visits for nicotine dependence, reduced cannabis relapse and lower risk of opioid overdose.
Early clinical trials
Randomized and early‑phase trials suggest that specific GLP-1 drugs can reduce craving and use for some substances, especially alcohol. Low‑dose semaglutide and dulaglutide have each been shown to decrease alcohol craving and drinking in alcohol use disorder, although results with older agents like exenatide are more mixed.
Why this could change addiction care
GLP-1 drugs appear to act on a shared vulnerability in the brain’s reward system, showing signals of benefit across multiple substances rather than targeting a single drug. Because GLP-1 medications are already widely prescribed in primary care for diabetes and obesity, they could, if trials confirm efficacy, be layered into routine care to help close a major treatment gap in addiction.
Open questions and cautions
GLP-1 medications are not yet approved specifically for addiction, and evidence is still emerging and somewhat heterogeneous across substances. Key unknowns include whether benefits persist after stopping the drug, whether the brain adapts over years of continuous use, and whether long‑term dampening of reward circuits might blunt everyday motivation or drive in some people.
via Blogger https://bit.ly/3Pmhh8M
Recent Comments